Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B | $1.35B |
| Cost of revenue | $392.40M | $362.60M | $343.00M | $345.20M | $344.40M | $301.60M | $292.20M | $262.90M |
| Gross profit | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B | $1.09B |
| Gross margin | 77.5% | 78.0% | 78.1% | 77.8% | 77.5% | 78.7% | 78.9% | 80.6% |
| Research and development | $278.90M | $263.30M | $267.70M | $280.70M | $276.20M | $254.60M | $271.10M | $253.40M |
| Selling, general and administrative | $561.20M | $522.20M | $602.90M | $514.60M | $502.00M | $465.70M | $491.90M | $421.40M |
| Operating expenses | $835.40M | $808.40M | $1.13B | $873.30M | $776.60M | $716.30M | $803.70M | $718.50M |
| Operating income | $513.20M | $477.60M | $96.80M | $334.60M | $411.20M | $394.80M | $289.90M | $373.00M |
| Operating margin | 29.5% | 29.0% | 6.2% | 21.5% | 26.8% | 27.9% | 20.9% | 27.5% |
| EBITDA | $562.20M | $555.60M | $398.70M | $464.30M | $469.00M | $446.50M | $373.20M | $451.20M |
| Interest income | $0 | $33.50M | $56.30M | $38.60M | $0 | $36.50M | $64.00M | $24.30M |
| Interest expense | $30.00M | $0 | −$20.40M | — | $37.40M | $0 | −$19.80M | — |
| Income before taxes | $519.80M | $459.00M | $90.40M | $348.40M | $400.20M | $433.90M | $390.10M | $402.80M |
| Income taxes | $278.40M | $78.30M | $26.20M | $56.10M | $64.30M | $70.30M | $45.10M | $40.70M |
| Net income | $241.40M | $380.70M | $91.20M | $290.30M | $331.50M | $363.60M | $384.30M | $3.07B |
| Net margin | 13.9% | 23.1% | 5.8% | 18.7% | 21.6% | 25.7% | 27.7% | 226.6% |
| EPS, basic | $0.42 | $0.66 | $0.16 | $0.50 | $0.57 | $0.61 | $0.65 | $5.14 |
| EPS, diluted | $0.42 | $0.66 | $0.16 | $0.50 | $0.56 | $0.61 | $0.65 | $5.13 |
| Diluted shares | 577.60M | 580.70M | 581.80M | 585.70M | 587.90M | 587.80M | 590.70M | 598.10M |
Figures describe Edwards Lifesciences shares, not any token. As of Aug 4, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.